Selected article for: "clinical manifestation and early diagnosis"
Author: Angileri, Salvatore Alessio; Petrillo, Mario; Meglio, Letizia Di; Arrichiello, Antonio; Rodà, Giovanni Maria; Ierardi, Anna Maria; Uberoi, Raman; Carrafiello, Gianpaolo
Title: Adverse Events in Coronavirus Disease Patients Management: A Pictorial Essay
  • Cord-id: 86vhqnok
  • Document date: 2020_7_21
    • ID: 86vhqnok
    Snippet: Clinical manifestation of coronavirus disease (COVID-19) varies from asymptomatic to severe clinical forms that can result in acute respiratory distress syndrome or in multiple organ dysfunction syndromes. There are no guidelines, based on randomized controlled trials, for the treatment of COVID-19 patients. The treatment is based on antiviral drugs, invasive and non-invasive ventilation supports, and anticoagulant therapy. This is a pictorial essay covering the multiple adverse events encounter
    Document: Clinical manifestation of coronavirus disease (COVID-19) varies from asymptomatic to severe clinical forms that can result in acute respiratory distress syndrome or in multiple organ dysfunction syndromes. There are no guidelines, based on randomized controlled trials, for the treatment of COVID-19 patients. The treatment is based on antiviral drugs, invasive and non-invasive ventilation supports, and anticoagulant therapy. This is a pictorial essay covering the multiple adverse events encountered during the treatment of COVID-19 patients in an area with a high pandemic incidence. Adverse events are defined as unexpected events following treatment for the infection. The cases described would be useful in aiding early diagnosis, limiting and improving the management of serious complications for patients, and allowing rapid and appropriate treatment.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and long term morbidity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ischemic stroke and administration route: 1
    • acute ischemic stroke and lmwh low molecular weight heparin: 1, 2
    • acute ischemic stroke and long term morbidity: 1
    • acute ischemic stroke and low molecular: 1, 2, 3, 4, 5
    • acute ischemic stroke and low molecular weight: 1, 2, 3, 4, 5
    • acute pulmonary embolism and administration route: 1
    • acute pulmonary embolism and lmwh low molecular weight heparin: 1
    • acute pulmonary embolism and lobar artery: 1
    • acute pulmonary embolism and low molecular: 1, 2, 3, 4, 5, 6
    • acute pulmonary embolism and low molecular weight: 1, 2, 3, 4, 5, 6
    • lmwh low molecular weight heparin and long term morbidity: 1
    • lmwh low molecular weight heparin and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long term morbidity and low molecular: 1